Roles of RegⅣ in neoplasms and clinical applications

doi:10.3760/cma.j.issn.1673-422X.2014.08.001

Abstract

Wu Yichen, Ying Lisha, Ling Zhiqiang. Roles of RegⅣ in neoplasms and clinical applications[J]. Journal of International Oncology, 2014, 41(8): 561-564.

［1］ Zheng HC, Sugawara A, Okamoto H, et al. Expression profile of the REG gene family in colorectal carcinoma［J］. J Histochem Cytochem, 2011, 59(1): 106-115. ［2］ Numata M, Oshima T, Yoshihara K, et al. Relationship between RegⅣ gene expression to outcomes in colorectal cancer［J］. J Surg Oncol, 2011, 104(2): 205-209. ［3］ Kobayashi Y, Niwa Y, Tajika M, et al. Serum tumor antigen REG4 as a useful diagnostic biomarker in gastric cancer［J］. Hepatogastroenterology, 2010, 57(104): 1631-1634. ［4］ He XJ, Jiang XT, Ma YY, et al. REG4 contributes to the invasiveness of pancreatic cancer by upregulating MMP7 and MMP9［J］. Cancer Sci, 2012, 103(12): 2082-2091. ［5］ Tamura H, Ohtsuka M, Washiro M, et al. Reg Ⅳ expression and clinicopathologic features of gallbladder carcinoma［J］. Hum Pathol, 2009, 40(12): 1686-1692. ［6］ Zheng HC, Xu XY, Yu M, et al. The role of Reg Ⅳ gene and its encoding product in gastric carcinogenesis［J］. Hum Pathol, 2010, 41(1): 59-69. ［7］ Naito Y, Oue N, Hinoi T, et al. Reg Ⅳ is a direct target of intestinal transcriptional factor CDX2 in gastric cancer［J］. PLoS One, 2012, 7(11): e47545. ［8］ Li XH, Zheng Y, Zheng HC, et al. REG Ⅳ overexpression in an early stage of colorectal carcinogenesis: an immunohistochemical study［J］. Histol Histopathol, 2010, 25(4): 473484. ［9］ Katsuno Y, Ehata S, Yashiro M, et al. Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffusetype gastric carcinomainitiating cells is inhibited by TGFβ［J］. J Pathol, 2012, 228(3): 391-404. ［10］ Vanderlaag K, Wang W, FayadatDilman L, et al. Regenerating isletderived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer［J］. Int J Cancer, 2012, 130(6): 1251-1263. ［11］ Wang F, Xu L, Guo C, et al. Identification of RegⅣ as a novel GLI1 target gene in human pancreatic cancer［J］. PLoS One, 2011, 6(4): e18434. ［12］ Miyagawa K, Sakakura C, Nakashima S, et al. Overexpression of RegⅣ in peritoneal dissemination of gastric cancer and its potential as a novel marker for the detection of peritoneal micrometastasis［J］. Anticancer Res, 2008, 28(2B): 1169-1179. ［13］ Kuniyasu H, Oue N, Sasahira T, et al. Reg Ⅳ enhances peritoneal metastasis in gastric carcinomas［J］. Cell Proliferat, 2009, 42(1): 110121. ［14］ Oue N, Kuniyasu H, Noguchi T, et al. Serum concentration of Reg Ⅳ in patients with colorectal cancer: overexpression and high serum levels of Reg Ⅳ are associated with liver metastasis［J］. Oncology, 2007, 72(56): 371-380. ［15］ Guo Y, Xu J, Li N, et al. RegⅣ potentiates colorectal carcinoma cell migration and invasion via its CRD domain［J］. Cancer Genet Cytogenet, 2010, 199(1): 38-44. ［16］ Tao HQ, He XJ, Ma YY, et al. Evaluation of REG4 for early diagnosis and prognosis of gastric cancer［J］. Hum Pathol, 2011, 42(10): 1401-1409. ［17］ Takayama R, Nakagawa H, Sawaki A, et al. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma［J］. J Gastroenterol, 2010, 45(1): 5259. ［18］ Hayashi T, Matsubara A, Ohara S, et al. Immunohistochemical analysis of Reg Ⅳ in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker［J］. Oncol Rep, 2009, 21(1): 95-100. ［19］ Mitani Y, Oue N, Matsumura S, et al. Reg Ⅳ is a serum biomarker for gastric cancer patients and predicts response to 5fluorouracilbased chemotherapy［J］. Oncogene, 2007, 26(30): 4383-4393. ［20］ Ying LS, Yu JL, Lu XX, et al. Enhanced Reg Ⅳ expression predicts the intrinsic 5fluorouracil (5FU) resistance in advanced gastric cancer［J］. Dig Dis Sci, 2013, 58(2): 414-422. ［21］ Legoffic A, Calvo E, Cano C, et al. The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target［J］. PLoS One, 2009, 4(10): e7495. ［22］ Kobunai T, Watanabe T, Fukusato T. REG4, NEIL2, and BIRC5 gene expression correlates with gammaradiation sensitivity in patients with rectal cancer receiving radiotherapy［J］. Anticancer Res, 2011, 31(12): 4147-4153. ［23］ Bishnupuri KS, Luo Q, Sainathan SK, et al. Reg Ⅳ regulates normal intestinal and colorectal cancer cell susceptibility to radiationinduced apoptosis［J］. Gastroenterology, 2010, 138(2): 616-626.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[14]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[15]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.

Roles of RegⅣ in neoplasms and clinical applications

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments